New York State Assembly

 
•  Summary 
 
•  Actions 
 
•  Committee Votes 
 
•  Floor Votes 
 
•  Memo 
 
•  Text 
 
•  LFIN 
 
•  Chamber Video/Transcript 

A07087 Summary:

A07087 Actions:

A07087 Committee Votes:

Committee:CONSUMER AFFAIRS AND PROTECTION   Chair:Kavanagh      
DATE:04/25/2017AYE/NAY:16/0  Action: Favorable refer to committee Codes        
Kavanagh
Aye
Palumbo
Aye
Abbate
Aye
McDonough
Aye
Quart
Aye
McKevitt
Aye
Buchwald
Aye
Stec
Aye
Solages
Aye
Simon
Aye
Dilan
Aye
Seawright
Aye
Rozic
Aye
Niou
Aye
Pheffer Amato
Aye
Williams
Aye

Committee:CODES   Chair:Lentol      
DATE:04/25/2017AYE/NAY:22/0  Action: Favorable         
Lentol
Aye
Graf
Aye
Schimminger
Aye
Giglio
Aye
Weinstein
Aye
McKevitt
Aye
Pretlow
Aye
Montesano
Aye
Cook
Aye
Ra
Aye
Cymbrowitz
Aye
Morinello
Aye
Titus
Aye
O'Donnell
Aye
Lavine
Aye
Perry
Aye
Zebrowski
Aye
Abinanti
Aye
Weprin
Aye
Mosley
Aye
Hevesi
Aye
Fahy
Aye

A07087 Floor Votes:

A07087 Text:

 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          7087
 
                               2017-2018 Regular Sessions
 
                   IN ASSEMBLY
 
                                      April 4, 2017
                                       ___________
 
        Introduced  by M. of A. CRESPO -- Multi-Sponsored by -- M. of A. ARROYO,
          BLAKE, CROUCH, HEVESI, JOYNER, LOPEZ, McDONOUGH, MURRAY, OTIS,  PALUM-
          BO,  PICHARDO,  RIVERA,  SEAWRIGHT, SIMON, THIELE, TITONE -- read once
          and referred to the Committee on Consumer Affairs and Protection
 
        AN ACT to amend the general business law, in relation to the price goug-
          ing of medicine
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section 1. The general business law is amended by adding a new section
     2  396-rrr to read as follows:
     3    §  396-rrr.  Price  gouging  of  medicine. 1. For the purposes of this
     4  section, "drug subject to a shortage" shall mean  any  drug  or  medical
     5  product  intended  for human use publicly reported as being subject to a
     6  shortage by the U.S.  food  and  drug  administration  on  its  website,
     7  provided,  however, that a drug or medical product shall only be consid-
     8  ered a "drug subject to a shortage" during the period of time that  such
     9  drug or medical product is listed as being subject to a shortage on such
    10  website.
    11    2.  No party within the chain of distribution of any drug subject to a
    12  shortage shall sell or offer to sell any such drug subject to a shortage
    13  for an amount which represents an unconscionably excessive price.
    14    3. Whether a price is unconscionably excessive is a  question  of  law
    15  for the court.
    16    (a)  The  court's  determination  that a violation of this section has
    17  occurred shall be based on any of the following factors:
    18    (i) that the amount of the excess in price is unconscionably extreme;
    19    (ii) that there was an exercise of unfair leverage  or  unconscionable
    20  means; or
    21    (iii)  a  combination of both factors in subparagraphs (i) and (ii) of
    22  this paragraph.

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD07926-01-7
        A. 7087                             2
 
     1    (b) In any proceeding commenced pursuant to subdivision four  of  this
     2  section, prima facie proof that a violation of this section has occurred
     3  shall include evidence that:
     4    (i)  the amount charged represents a gross disparity between the price
     5  of the drug subject to a shortage which was the subject  of  the  trans-
     6  action and their value measured by the price at which such drug was sold
     7  or  offered  for  sale  by the defendant in the usual course of business
     8  immediately prior to the onset of the shortage; and
     9    (ii) the amount charged grossly exceeded the price at which  the  same
    10  or  similar  drug  subject to a shortage was readily obtainable by other
    11  purchasers in the trade area. A defendant may rebut a prima  facie  case
    12  with  evidence  that  additional  costs  not  within  the control of the
    13  defendant were imposed on the defendant for the drug subject to a short-
    14  age.
    15    4. Where a violation of this section is alleged to have occurred,  the
    16  attorney general may apply in the name of the People of the State of New
    17  York  to  the  supreme  court within the judicial district in which such
    18  violation is alleged to have occurred, on notice of five  days,  for  an
    19  order  enjoining or restraining commission or continuance of the alleged
    20  unlawful acts. In any such proceeding, the court shall  impose  a  civil
    21  penalty  in  an  amount  not to exceed one hundred thousand dollars and,
    22  where appropriate, order restitution to aggrieved consumers.
    23    5. Prior to applying for an order from the supreme court  pursuant  to
    24  subdivision  four of this section, the attorney general, in consultation
    25  with the department of  health,  shall  consider  the  pricing  dynamics
    26  unique to the small and independent distributors within the supply chain
    27  including,  but not limited to, the price charged by the end use dispen-
    28  ser relative to its acquisition cost.
    29    § 2. This act shall take effect immediately.